EANM 2017 Setting new standards with molecular imaging.

October 21-25, 2017
Technical Exhibition: October 22-24, 2017
Siemens Healthineers Hall X4, Booth #401

Siemens Healthineers is committed to becoming the trusted partner of healthcare providers worldwide, enabling them to improve patient outcomes while reducing costs. Visit the booth to see live demos and learn more about all our products including the recently introduced Symbia Intevo Bold.TM1

The future of PET/CT is here

The future of PET/CT is here.
See it unveiled.
Sunday, October 22nd
9:45 a.m., Hall X4,
Siemens Healthineers booth 401


Siemens Healthineers Lunch Symposium

Siemens Healthineers Lunch Symposium
Leading experts in molecular imaging will share insights into the most recent advances in SPECT/CT and PET/CT.
Monday, October 23, 2017
1:00 p.m.-2:30 p.m., Hall K

Product Highlights

The future of PET/CT

The future of PET/CT will create real clinical, operational and financial benefits for our customers.

Biograph Horizon Flow edition

The Biograph HorizonTM Flow edition2 with FlowMotionTM technology enables standardized indication-based protocols, adjusted to the patient’s anatomy, all in a single scan.

Biograph mCT Flow

Biograph mCT FlowTM with FlowMotion technology combines our standard-setting PET/CT with a unique system design that enables continuous motion of the patient table—allowing increased image quality, greater patient comfort, better performance and expanded versatility.

FlowMotion Technology

FlowMotion continuous bed motion technology, enables standardized indication-based protocols, adjusted to the patient’s anatomy, all in a single scan–-personalizing the patient experience while optimizing the workflow.

Biograph mMR

With Biograph mMR MR/PET you can set the pace in diagnostic imaging, by combining leading 3T MRI performance with proven molecular imaging, fully integrated in one system.

Symbia Intevo Bold

A better image for every body.3 For those who want more from SPECT/CT. We made high-performance CT even better with the Symbia Intevo Bold.™2

Symbia Intevo

Priorities in healthcare are shifting. Better care no longer means more care. It means more effective care. Now, you can discover expanded clinical reach and a higher standard of care and distinction for your organization−with the hybrid SPECT/CT technology of Symbia Intevo.TM

xSPECT Technologies

Expanded xSPECT QuantTM2 now offers automated, accurate and reproducible quantification of 99mTc, 123I, 177Lu4 and 111In. This extends the use of advanced SPECT/CT quantification from general nuclear medicine and bone studies to indications including neurological disorders, neuroendocrine tumors, neuroblastoma and metastatic prostate cancer. xSPECT BoneTM provides higher resolution and increased clinical detail to support physicians’ ability to more confidently characterize disease state. xSPECT,™ the true integration of SPECT and CT.

syngo.via for MI

Save time, cost and effort with one reading solution engineered for greater productivity and accuracy: syngo® .via for Molecular Imaging is available for both PET/CT, SPECT and SPECT/CT.



Topic Area


Assessment of whole-body scatter correction for Ga-68 PSMA PETCT


Harshali Bal, Inki Hong, Florian Buther, Mehmet Aykac, Klaus
Schafers, Maurizio Conti

First human images from a next generation SiPM based PET/CT system


Mike Casey, Ziad Burbar, Harold Rothfuss, Vladimir Panin, Deepak
Bharkhada, William Howe, Yong Bradley

Quantitative Y-90 PET for dosimetry applications


Yuni Dewaraja, Hongki Lim, Neal Clinthorne, Jeffrey Fessler, Yuni Dewaraja, Maurizio Conti

Using EQ.PET to reduce reconstruction-dependent variation in FDG PET brain imaging


M. Vanhoutte, R. Lopes, F. Semah, R. Fahmi

Comparison of an image-based to an atlas-based volume of interest for DaTScan quantification


Rachid Fahmi, Sven Zuehlsdorff

Estimation and reliability of myocardial blood flow after motion correction with dynamic PET using a Bayesian framework


Antione Saillant, Kimberley Saint, Matthew Memmott, Ian Armstrong, Vijay Shah, Sven Zuehlsdorff, Jérôme Declerck, Mark Jenkinson, Michael Chappell

Robustness of EQ-PET SUV harmonization to tumor-to-background variation


Bruce Spottiswoode, Vittoria Mattoli, Margherita Milite, Maria Lucia
Calcagni, Alessandro Giordano, Luca Indovina

Quantitative SPECT Neuroimaging using a Data Driven Estimation of Attenuation from the Projection Data Alone


Xinhong Ding, A. Hans Vija

Assessment of Statistical Dose Uncertainty Propagation for Lu1771 SPECT Imaging with an Automated Internal Dosimetry Research Tool as a result of fast SPECT Acquisition Protocols


A. Hans Vija, Michal Cachovan

Diagnostic value of quantitative 99mTc-DPD-SPECT/CT for the detection of prosthetic loosening in patients with hip and knee joint replacement.


Martin Braun, Michal Cachovan, Geert Pagenstert, Damian Wild, Martin Kretzschmar

Assessment of Dose Uncertainty Propagation using standardized Quantitative Lu1774 SPECT Imaging and an Automated Internal Dosimetry Research Tool


A. Hans Vija, Michal Cachovan

First Clinical Experience with Ultra-High Resolution Multi-Focal Collimators for Tc-99m-PSMA Imaging


Christian Schmidkonz, Claudia Hollweg, James C. Sanders, Michael Beck, Daniela Schmidt, A. Hans Vija, Torsten Kuwert, Philipp Ritt

xSPECT derived absolute SUV: An emerging accurate tool for I-123-ioflupane analysis


M. Jreige, F. Tabotta, M. Nicod Lalonde, R. Fahmi, N. Schaefer, G. Allenbach, J. O. Prior

Key Presentations

Plenary 1 – Sunday, October 22




Hall A, 10:00-11:15

Theranostic Developments for Prostate Cancer (incl. Marie Curie Lecture)
Chairs: Dr. Kristoff Myulle, Prof. Francesco Giammarile
Prof. Jochen Walz (FR): Clinical Aspects
Prof. Ken Herrmann (DE): PSMA Imaging – Which Knife is the Sharpest?
Prof. Uwe Haberkorn (DE): Marie Curie Lecture: PSMA Labelled with Alfa-Emitters

Sunday, October 22, 2017




08:00 - 09:30

CME 1-Physics-Challenges and Solutions for MR-Based Attenuation Correction of PET


08:00 - 08:30

Volkmar Schulz (Aachen): Introduction to MR-Based AC


08:30 - 09:00

Ninon Burgos (London): MR Based Attenuation Correction for Brain


09:00 – 09:30

Georg Schramm (Leuven): MR Based Attenuation Correction for the Body

 Monday, October 23, 2017




08:00 - 09:30

CME 5-Radiopharmacy/ Drug Development/ Radionuclide Therapy/ SNMMI-Theranostics and Companion Drugs


 08:00 - 08:30

 08:00 - 08:30 Hans-Jürgen Wester (Munich): Theranostic Concepts, Exemplified on PSMA and CXCR4


 08:00 - 08:30

 Karl Herholz (Manchester): Brain PET and SPECT in Patients with Fronto-Temporal Dementia


 08:00 - 09:30

 Committee Symposium 2-Neuroimaging/Physics-PET/MR – Making it Clinical


 08:00 - 08:25

 Claes Ladefoged (Copenhagen): Attenuation Correction - Is it Solved?


 08:25 - 08:45

 Ian Law (Copenhagen): Brain Tumours


 08:30 - 09:00

 Nicola Pavese (London): Brain PET and SPECT Imaging in Lewy Body Diseases


 08:30 - 09:00

 Cathy Cutler (SNMMI, Upton): Development of Novel Theranostics


 08:45 - 09:05

 Alexander Hammers (London): Epilepsy - What does Simultaneous PET-MR Achieve that PET+MR does not?


 09:05 - 09:30

 Alexander Drzezga (Cologne): Dementia


 09:00 - 09:30

 Jacques Barbet (Nantes): Pretargeting in the Context of Theranostics and Companion Diagnostics


 09:00 - 09:30

 Javier Arbizu (Pamplona): Brain SPECT and PET in Tau-Related Parkinsonism


 11:30 - 13:00

 Bone & Joint-Skeletal Scintigraphy Today – Accurate Diagnosis of Bone Disease with Therapeutic Impact


 11:30 - 11:50

 Philipp Ritt (Erlangen): High Resolution SPECT/CT and Beyond


 11:30 - 13:00

 CME 10-Neuroimaging-Brain PET and SPECT in Dementia – Beyond Alzheimer’s Disease


 11:50 - 12:10

 Torsten Kuwert (Erlangen): SPECT/CT Quantification


 12:10 - 12:40

 Zohar Keidar (Haifa): The End of Planar: Whole-Body SPECT as New Paradigm


 12:40 - 13:00

 Gopinath Gnanasegaran (London): Top Ten Diagnoses Made Possible by SPECT/CT


 14:30 - 16:00

 Do.More–Committee Symposium-Dosimetry-Validation of Quantitative Imaging, Dosimetry & Estimates of Uncertainty


 14:30 - 14:50

 Frédéric Courbon (Toulouse): The Need for Dosimetry Validation - A Clinician’s


 14:50 - 15:10

 Johan Ruben Gustafsson (Lund): The Use of Monte Carlo for Validation and Uncertainty Analysis


 15:10 - 15:30

 Jonathan Gear (London): Propagation of Uncertainty Analysis for Absorbed Dose Calculations


 15:30 - 15:50

 Andrew Robinson (Teddington): Validation of Calibration Protocols and the


 16:30 - 18:00

 CME 8-Radionuclide Therapy/Radiopharmacy/Dosimetry-Clinical Trial Design for Radionuclide Therapy


 17:30 - 18:00

 Rebecca Gregory (London): Dosimetry for Clinical Trials

 Wednesday, October 25, 2017




 08:00 - 09:30

 CME 13-Dosimetry/Radionuclide Therapy/Radiation Protection-Treatment Planning for Radionuclide Therapy, How Simple Can it Be? 


 08:45 - 9:05

 Samer Ezzidin (Homburg): Are Traditional Fixed Activity Schedules Appropriate for Advancing in Personalised Medicine?


 09:05 – 9:20

 Katarina Sjögreen Gleisner (Lund): Examples of Workflow and Requirements for Patient-Specific Dosimetry-Guided Treatments